Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Cough: full-pipeline trial registry

4 of 13 indexed Cough trials are currently recruiting.

Corpus placement: #1,315 of 28,707 conditions by registered trial count.

13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count

Cough: 13 US clinical trials tracked, 4 recruiting.

Cough is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Bellus Health Inc. - a GSK company, running 3 of these trials.

Enrollment posture brief

Registry condition cough

OPEN 4 | RECR 31% | LATE 4 | EARLY 4 | RANK #1315 | SPON 3

Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)

ACL Injury61.5%Acute Biphenotypic Leukemia46.2%Cough (this)31%Accidental Falls30.8%Actinic Keratoses23.1%
Open-enrollment share among volume-matched conditions near Cough

Cough lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cough on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cough is recruiting below its size-band peers.

    4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cough research.

    Bellus Health Inc. - a GSK company accounts for 3 of 13 trials (23.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cough enrolment sits around 60 participants.

    Median target enrolment is 60 among the 13 trials that report a genuine target (sentinel values excluded). 7 of those (53.8%) plan for fewer than 100 participants.

  4. Cough research is mostly interventional.

    11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 32Phase 42

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 3 975 participants

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Bellus Health Inc. - a GSK company

NCT05600777

RECRUITING Phase 4 160 participants

The Mechanism Versus PPI Trial

University of California, San Diego

NCT06999577

RECRUITING NA 60 participants

Stimulation of the Larynx to Treat Unexplained Chronic Cough

University of Minnesota

NCT05273190

RECRUITING 50 participants

Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough

University of Alabama at Birmingham

NCT04642352

ACTIVE NOT RECRUITING Phase 3 825 participants

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Bellus Health Inc. - a GSK company

NCT05599191

ACTIVE NOT RECRUITING 39 participants

Work of Breathing Assessment in Triage Scale

CHRISTUS Health

NCT05479929

COMPLETED Phase 4 244 participants

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

HALEON

NCT06716645

COMPLETED NA 120 participants

Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents

Penn State University

NCT01721395

COMPLETED Phase 1 105 participants

Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep

Penn State University

NCT00127686

COMPLETED Phase 1 32 participants

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

Bellus Health Inc. - a GSK company

NCT06222892

COMPLETED Phase 1 22 participants

Cough Desensitization Therapy: Pilot 2

University of Montana

NCT05226299

COMPLETED Early Phase 1 19 participants

Cough Desensitization Therapy for Cough Hypersensitivity Syndrome

University of Montana

NCT04256733

COMPLETED NA 12 participants

Stimulation With Wire Leads to Restore Cough

MetroHealth Medical Center

NCT01659541

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 3 2
Phase 4 2

Named interventions

Most-linked intervention names on Cough records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

BLU-5937 Drug
2 trials
Placebo Drug
2 trials
Agave Syrup Dietary supplement
1 trials
Buckwheat Honey Drug
1 trials
Camlipixant Drug
1 trials
Robitussin Maximum Strength Nighttime Cough DM Drug
1 trials
Robitussin Maximum Strength Cough and Chest Congestion DM Drug
1 trials
Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer Biological
1 trials

US sites by state

Facility locations filed on Cough trials. A trial with sites in several states counts in each.

Florida 3 trials
California 3 trials
Texas 2 trials
Pennsylvania 2 trials
Montana 2 trials
Georgia 2 trials
Colorado 2 trials
Arizona 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cough page

13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cough condition card totals 13 registered trials; most-linked intervention BLU-5937; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.